Progesterone receptor
19
MENTIONS
8
EPISODES
6
PODCASTS
Search complete. 19 mentions across 8 episodes found for "Progesterone receptor".
Oct 26, 2026
Pedram RazaviGUEST
So based on these three receptors, we categorize breast cancer.
Pedram RazaviGUEST
If they are ER or PR positive and HER2 negative, it means that the amount of HER2 on the surface is like normal.
Pedram RazaviGUEST
It's not excessive.
Pedram RazaviGUEST
We call them ER positive, HER2 negative, or hormone receptor HER2 negative.
Kandas RodarteHOST
HER2, progesterone, and estrogen.
Kandas RodarteHOST
So you could have PR positive, PR negative, ER positive, ER negative, PR positive, PR negative.
Kandas RodarteHOST
And you put all those combinations together.
Kandas RodarteHOST
So those are all different types.
SamHOST
So for this episode, some of our new updates are going to include PIK3CA therapies, ESR1 directed therapies, an update on our first line HER2, and updates on high PD-L1 breast cancers.
SamHOST
So Corrine, we are going to again break this down based on, you know, receptor status.
SamHOST
ERPR positive, HER2 positive, as well as triple negative.
SamHOST
So So first we're going to start off with ERPR-positive metastatic breast cancer.
SamHOST
How are we treating these ladies?
CorrineHOST
So we are thinking about frontline aromatase inhibitor.
SamHOST
So the P of penias is palbocyclops.
SamHOST
So hopefully that'll help you guys remember when you're thinking about these side effects on test day or in the real world.
Ralph OkoHOST
Oh.
Robert StickelGUEST
Um, and we talked about the, those tumors having those receptors, um, for those hormones, the estrogen receptor positive and progesterone receptor positive tumors, the ER positive, PR positive.
Robert StickelGUEST
When you're pregnant, if your tumor biology is to have those receptors and you're pregnant and you're making estrogen, progesterone, it's a real problem because-
Ralph OkoHOST
Is it all
Robert StickelGUEST
And the, those hormones serve as fuel for the, for the tumor.
Robert StickelGUEST
They're called estrogen receptor positive tumors and progesterone receptor positive tumors.
Robert StickelGUEST
We, we abbreviate that, call it ER positive and PR positive, which means that the tumor has those receptors, and then estrogen comes in and is, and makes its way to the tumor.
Robert StickelGUEST
It serves as fuel to make the tumor grow.
Robert StickelGUEST
So the, um, there are certain t- times when you, if you're, if you're exposed to estrogen for long periods of time, um, early, uh, onset of, uh, your menstrual period and a very late menopause, which would mean you start your m- your menstrual cycle early and you have a very late menopause, that'd be a lot of years of un- of, uh, exposure to estrogen.
SamHOST
So this week's episode we're gonna be focusing on treatment options for localized breast cancer.
SamHOST
We're gonna go into all the important details on radiation as well as therapies based on what the ER, PR, HER2 receptor status is.
SamHOST
So in terms of prevalence, 70, 80% of breast cancers are ER, PR positive, so hormonally driven.
SamHOST
15 to 20% are HER2 positive, and then that remainder of 15 to 20% are what we call triple negative, so negative for ER, PR and HER2.
SamHOST
This topic is constantly changing, so we make sure to stay up to date, um, when we're talking about treating patients with breast cancer, and always reference your NCCN guidelines and of course study this before your boards and test day.
SamHOST
So there are a few updates since we did this last year in the terms of adjuvant CDK 4/6 inhibitors, adjuvant HER2 therapy, and more.
CorrineHOST
Absolutely.
CorrineHOST
And so these are patients over the age of 70 with a tumor under two centimeters that are clinically node negative that are ER positive, they can go to endocrine therapy alone based on the CALGB 9343 trial.
Christine Brezden-MasleyGUEST
The last one, the last subtype that we have is known as a triple-negative breast cancer, and we call it triple-negative because this cancer is slightly more aggressive.
Christine Brezden-MasleyGUEST
It's mutated off the estrogen receptor, the other female sex receptors, known as progesterone receptor, and it also is not expressing HER2.
Christine Brezden-MasleyGUEST
So these are the three negatives, ER negative, PR negative, HER2 negative.
Christine Brezden-MasleyGUEST
And triple-negative breast cancers are associated with, um, individuals who have, say, a germline BRCA mutation.
Christine Brezden-MasleyGUEST
This is a D, big DNA repair protein, uh, whereby women are, have a high incidence of de- developing breast cancer.
Jay ChaplinHOST
Hard to say in this environment.
Jay ChaplinHOST
Uh, what type of genomic testing is needed beyond an Oncotype DX and general breast cancer genetic tests? I have ER, PR positive, HER2 negative, eight millimeter tumor, KI 67 5%.
Jay ChaplinHOST
So, um, KI 67, for those of you who don't know, is a marker of cell division.
Jay ChaplinHOST
The faster the cells are dividing, the higher the KI 67 percentage will be.
Jay ChaplinHOST
If you're going for a blood sample, Tempus is just as good and much easier to work with.
Jay ChaplinHOST
Um, I can say more about that later.
Jay ChaplinHOST
Um, at this point, if you've got ER, PR positive, HER2 negative, you're probably being pushed down the standard aromatase inhibitor pathway.
Jay ChaplinHOST
And at the moment, there's not a lot of utility other than looking for estrogen receptor one mutations, which again, are absolutely critical because now we've got two drugs on the market, camizestrant and imelestrant, that if you develop an ESR1 mutation, you can switch onto these better drugs and have a much better prognosis.